# EDGAR Filing Document

**Accession Number:** 0001512717
**File Stem:** 0001193125-25-202241
**Filing Date:** 2025-9
**Character Count:** 4520
**Document Hash:** 1607eb7d2d2f1c05fbbb39974063e8ad
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-202241.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001193125-25-202241

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20250912

**FILED AS OF DATE**: 20250912

**DATE AS OF CHANGE**: 20250912

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Theratechnologies Inc.
- **CENTRAL INDEX KEY:** 0001512717
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A8
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35203
- **FILM NUMBER:** 251311768

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2015 PEEL STREET
- **STREET 2:** 11TH FLOOR
- **CITY:** MONTREAL
- **PROVINCE COUNTRY:** A8
- **BUSINESS PHONE:** 1 438-858-3967

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 2015 PEEL STREET
- **STREET 2:** 11TH FLOOR
- **CITY:** MONTREAL
- **PROVINCE COUNTRY:** A8

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER** 

**PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**For the month of September 2025.** 

**Commission File Number 001-35203** 

## Theratechnologies Inc.
**(Translation of registrant's name into English)** 

**2015 Peel Street, Suite 1100** 

**Montreal, Quebec** 

**H3A 1T8, Canada** 

**(Address of principal executive office)** 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☒ Form 20-F ☐ Form 40-F

------

**<u>EXHIBIT INDEX</u>**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| 99.1 | [Report on Voting Results Following the Special Meeting of Shareholders Held on September 12, 2025](d28243dex991.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| **THERATECHNOLOGIES INC.** | **THERATECHNOLOGIES INC.** |
| By: | /s/ Jocelyn Lafond |
| Name: | Jocelyn Lafond |
| Title: | General Counsel and Corporate Secretary |

---

Date: September 12, 2025

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g28243g0913001744364.jpg)

**REPORT ON VOTING RESULTS** 

**SPECIAL MEETING OF SHAREHOLDERS** 

**HELD ON SEPTEMBER 12, 2025** 

The Special Meeting of Shareholders (the "**Meeting**") of Theratechnologies (the "**Corporation**") was held in a hybrid format on Friday, September 12, 2025, at 10:00 a.m. (Eastern Time). In accordance with section 11.3 of Regulation 51-102, we hereby advise you of the following voting results as tabulated. Accordingly, at the Meeting, there were 20,873,134 common shares represented in person (including virtually) or by proxy, representing 45.4% of the 45,980,019 shares of the Corporation issued and outstanding on August 13, 2025, being the record date for the Meeting.

**<u>Approval of the Arrangement Resolution</u>**

The arrangement resolution set forth in Appendix C of the Corporation's management proxy circular dated August 12, 2025 filed on the Corporation's SEDAR+ profile at <u>www.sedarplus.ca</u> was adopted on a vote by way of ballot by (i) at least 66 <sup>2</sup>⁄<sub>3</sub>% of the votes cast thereon by the holders of common shares present in person or virtually or represented by proxy at the Meeting, and (ii) at least a simple majority of the votes cast thereon by the holders of common shares present in person or virtually or represented by proxy at the Meeting, excluding the votes cast by holders of common shares required to be excluded pursuant to Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*.

The voting results are set out below:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Votes For** | **Votes For** | **Votes Against** | **Votes Against** |
| | **#** | **%** | **#** | **%** |
|  All shareholders | 20339785 | 97.44% | 533349 | 2.56% |
|  All shareholders (excluding the votes cast by holders of common shares required to be excluded pursuant to Multilateral Instrument 61-101 – *Protection of Minority Security Holders in Special Transactions*) | 20185161 | 97.43% | 533349 | 2.57% |

---